Enrique Poradosu, Chief Science & Business Officer at Nuvectis Pharma, Inc. (NVCT), bought 500 shares at $11.55 ($6K) on 2023-03-27, disclosed to the SEC on 2023-03-28.
Open-market purchase of $6k NVCT by Chief Science & Business Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| NVCT | BUY | 2022-05-16 | $10K | — | Filing → |
| NVCT | BUY | 2022-02-08 | $16K | — | Filing → |